Search
for

    Sort by

    Research 301–330 of 1000+

    1. MicroRNA-1246 Inhibits NFATc1 Phosphorylation and Regulates T Helper 17 Cell Activation in the Pathogenesis of Severe Alopecia Areata 2023
    2. Comparative Efficacy and Adverse Clinical Events of Methotrexate versus Azathioprine with Steroid Mini Pulse Therapy in the Management of Moderate to Severe Alopecia Areata: A Tertiary Centre Based Interventional Study Nepal Journal of Dermatology Venereology & Leprology · 2022
    3. Comparison of effectiveness of weekly azathioprine pulse (WAP) and betamethasone oral mini pulse (BOMP) in the treatment of moderate to severe alopecia areata Journal of The American Academy of Dermatology · 2015
    4. Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata European Journal of Dermatology · 2019 · 10 citations
    5. 76957 Efficacy and Safety of Upadacitinib in Adolescents and Adults with Severe Alopecia Areata: A Subgroup Analysis of the UP-AA Phase 3 Clinical Program Journal of the American Academy of Dermatology · 2026
    6. 74643 Deuruxolitinib improves scalp hair regrowth over time in patients with severe alopecia areata: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials Journal of the American Academy of Dermatology · 2026
    7. Real-world retrospective study with upadacitinib in patients with severe alopecia areata: A series of 23 cases JAAD Case Reports · 2026
    8. Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA) SKIN The Journal of Cutaneous Medicine · 2025
    9. 61346 Baseline Psychosocial Impact of Disease in Patients with Severe Alopecia Areata Treated with Baricitinib Recruited from the US Customer Support Program Journal of the American Academy of Dermatology · 2025
    10. 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata Journal of the American Academy of Dermatology · 2023
    11. Randomized Study to Evaluate the Efficacy of Platelet Rich Plasma, Intralesional Triamcinolone Acetonide and Intralesional Normal Saline in Moderate to Severe Alopecia Areata Journal of evolution of medical and dental sciences · 2022
    12. Comorbid Bronchial Asthma, Atopic Dermatitis and Hashimoto's Thyroiditis Are Risk Factors for Early‐Onset, Severe and Prolonged Alopecia Areata Allergy · 2025 · 2 citations
    13. An Atypical Female Case of Ichthyosis Follicularis, Alopecia, and Photophobia (IFAP) Syndrome with Severe Lower Limb Contractures Requiring Orthopedic Surgery Clinical Cosmetic and Investigational Dermatology · 2025
    14. 63407 A Descriptive Analysis of Patients With Moderate-to-Severe Atopic Dermatitis and Comorbid Alopecia Areata in the Abrocitinib JADE Clinical Program Journal of the American Academy of Dermatology · 2025
    15. 77015 Subgroup Analysis of Efficacy of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata From the UP-AA Phase 3 Program Journal of the American Academy of Dermatology · 2026
    16. 74582 Early improvement in scalp hair regrowth with deuruxolitinib in patients with severe alopecia areata: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials Journal of the American Academy of Dermatology · 2026
    17. P46 PSYCHOMETRIC PERFORMANCE OF EQ-5D-5L INDEX IN ADULTS AND ADOLESCENTS WITH SEVERE ALOPECIA AREATA: EVIDENCE FROM PHASE III TRIAL DATA Value in Health · 2026
    18. RETRACTION: Observing the Clinical Efficacy of Combined Serum Microneedle Therapy for Moderate to Severe Androgenetic Alopecia in Scalp Repair Skin Research and Technology · 2025
    19. 73192 Consistent Efficacy of Upadacitinib in Alopecia Areata Subgroups: Adult, Pediatric, Severe Disease, and JAK-Refractory Patients — A Meta-Analysis Journal of the American Academy of Dermatology · 2026
    20. Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata Anais Brasileiros de Dermatologia · 2024 · 4 citations
    21. PCR30 PSYCHOMETRIC EVALUATION OF SKINDEX-16 AA, THE ALOPECIA AREATA SYMPTOM IMPACT SCALE (AASIS), AND THE SCALP HAIR ASSESSMENT PATIENT-REPORTED OUTCOME (PRO) IN ADULTS AND ADOLESCENTS WITH SEVERE ALOPECIA AREATA Value in Health · 2026
    22. Publisher Correction: Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib Dermatology and Therapy · 2024
    23. Alopecia Areata: Current Treatments and New Directions American Journal of Clinical Dermatology · 2023 · 57 citations
    24. BH09 Patient experience of off-label Janus kinase inhibitor use for alopecia areata in a cohort of 34 patients from a single UK practitioner: exploring changing trends in healthcare provision and access to drug treatments 2023
    25. Public Interest in Janus Kinase (JAK) IInhibitors for Alopecia Areata: A Google Trend Analysis JMIR Dermatology · 2026
    26. Efficacy and safety of janus kinase inhibitors in the treatment of alopecia areata in children Medical alphabet · 2025
    27. Clinical and demographic factors associated with nail involvement in adult alopecia areata patients at Al-Kadhmia teaching hospital, Baghdad, 2023 International Journal of Dermatology Sciences · 2025
    28. LB792 Minoxidil and dutasteride drug tattooing for male Androgenetic Alopecia Journal of Investigative Dermatology · 2021
    29. Male balding is a major risk factor for severe COVID-19 Journal of The American Academy of Dermatology · 2020 · 29 citations
    30. Association between androgenetic alopecia and cardiovascular risk factors according to BASP classification in Korean androgenetic alopecia 2016